At Humanigen, Inc. we are committed to working with strategic and commercial partners, medical and academic institutions to maximize product and technology portfolio. We are dedicated to working in partnerships and collaborations to add value and fill unmet medical needs in life threatening conditions such as COVID-19, CAR-T, GvHD, CMML, Eosinophilic Diseases, GBM and other solid tumors. 

Humanigen Fact Sheets

  • Corporate
  • Cytokine Storm
  • Lenzilumab

Humanigen’s portfolio is broad and currently, we are open to strategic partnership discussions in the areas of:​​

Lenzilumab™ COVID-19 prevention / treatment of Hyper-inflammation / Cytokine Storm

Phase 3 & Launch

Lenzilumab CAR-T increased efficacy and safety

Phase 1/2

Lenzilumab Eosinophilic Asthma

Phase 3

Ifabotuzumab Solid tumors

Phase 2

EMR1 Eosinophilic diseases

Phase 1/2

Early stage opportunities for innovative programs with our proprietary CARs


Key areas we are looking for in Lenzilumab partners are:


Multinational, Regional or Domestic Pharmaceutical or Biotechnology Company


Global, Regional and Countries such as People’s Republic of China, Latin America, Russia, India and certain other Asia-Pacific countries are available for discussion


Lenzilumab (currently 10mg/ml filled into a 10ml vial)


Treatment of hypoxic hospitalized COVID-19 pneumonia patients; treatment and prevention of CAR-T CRS and neurotoxicity and improvement in CAR-T efficacy

Clinical development:

Partner to complete required clinical development suitable for registration in the Territory


Partner to submit for approval in the territory for the Indication.  Partner is free to reference EUA, BLA and any other approvals


Ideally partner will have experience in the manufacturing of mAbs and will complete the tech transfer of the process (to cGMP standard) from our current CMO’s.  If no manufacturing capability exist, partner may find a suitable CMO to supply Product. Alternatively, Partner may be able to purchase Product from Humanigen.


Partner will need to have existing commercial infrastructure to commercialize and distribute lenzilumab to hospitals and other relevant institutions.

If you have an interest in Humanigen, or any of its portfolio or technologies to work together and achieve great outcomes for patients and their families, then please get in contact with:

Bob Atwill at:


Humanigen, Inc. currently has a number of Partners and Collaboration.

National Institute of Allergy and Infectious Diseases (“NIAID”)


Kite Pharmaceuticals, Inc.

CAR-T Therapies



Humanigen, Inc. also has exclusive worldwide license agreements with the University of Zurich in GvHD and the Mayo Foundation for Medical Education and Research in CAR-T.

Humanigen Australia Pty Ltd has been established and the current Australian Trials and Partners are listed below:

C-SMART (COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomized Trial)

Lenzilumab in cancer patients who are COVID-19 positive and have pneumonia

PREACH-M (PREcision Approach to CHronic Myelomonocytic Leukaemia)

Lenzilumab in refractory chronic myelomonocytic leukemia (CMML)

Ifabotuzumab in glioblastoma multiforme (GBM)

Follow Us

  • Twitter
  • LinkedIn
  • Facebook

©2021 Humanigen, Inc.  All rights reserved